Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

BACKGROUND AND AIM: Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis. METHODS: Patients, started on saroglitazar 4 mg w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhuri, Sujit, Dutta, Agnibha, Chakraborty, Sunil Baran Das
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037031/
https://www.ncbi.nlm.nih.gov/pubmed/36968568
http://dx.doi.org/10.1002/jgh3.12878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037031/
https://www.ncbi.nlm.nih.gov/pubmed/36968568
http://dx.doi.org/10.1002/jgh3.12878

Ejemplares similares